Opinion|Videos|August 1, 2024
Unmet Needs in IPF Landscape
Author(s)Justin Oldham, MD, MS
Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the current unmet needs in IPF treatment and why is it necessary to develop new pharmacotherapies for this disease?
- What biomarkers are currently used for the diagnosis of IPF?
Advertisement
Related to this article
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
3
Disability, Economic Toll of Multimorbidity Climb in Older Adults
4
October FDA Approvals Bring Advances Across 5 Specialties
5